At close: December 13 at 4:00:02 PM EST
After hours: December 13 at 4:00:22 PM EST
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
Total Revenue
--
--
15,000.00
--
Operating Expense
72,429.00
--
25,483.00
6,694.00
Operating Income
-72,429.00
--
-10,483.00
-6,694.00
Net Non Operating Interest Income Expense
2,189.00
--
--
--
Other Income Expense
93.00
--
19.00
-869.00
Pretax Income
-70,147.00
--
-10,464.00
-7,563.00
Tax Provision
-179.00
--
347.00
--
Net Income Common Stockholders
-69,968.00
--
-10,811.00
-7,563.00
Diluted NI Available to Com Stockholders
-69,968.00
--
-10,811.00
-7,563.00
Basic EPS
-2.74
-2.74
-0.42
-0.30
Diluted EPS
-2.74
-2.74
-0.42
-0.30
Basic Average Shares
25,533.53
25,533.53
25,533.53
25,533.53
Diluted Average Shares
25,533.53
25,533.53
25,533.53
25,533.53
Total Operating Income as Reported
-72,429.00
--
-10,483.00
-6,694.00
Total Expenses
72,429.00
--
25,483.00
6,694.00
Net Income from Continuing & Discontinued Operation
-69,968.00
--
-10,811.00
-7,563.00
Normalized Income
-69,968.00
--
-10,811.00
-7,563.00
Interest Income
2,189.00
--
--
--
Net Interest Income
2,189.00
--
--
--
EBIT
-72,429.00
--
-10,483.00
-6,694.00
EBITDA
-72,414.00
--
-10,475.00
-6,692.00
Reconciled Depreciation
15.00
--
8.00
2.00
Net Income from Continuing Operation Net Minority Interest
-69,968.00
--
-10,811.00
-7,563.00
Normalized EBITDA
-72,414.00
--
-10,475.00
-6,692.00
Tax Rate for Calcs
0.00
--
--
--
12/31/2021 - 6/25/2021
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
UpgradeRelated Tickers
TARS Tarsus Pharmaceuticals, Inc.
52.50
+2.78%
CNTA Centessa Pharmaceuticals plc
16.57
-1.78%
VRDN Viridian Therapeutics, Inc.
17.85
-0.78%
RNAC Cartesian Therapeutics, Inc.
18.69
-7.13%
RGNX REGENXBIO Inc.
8.28
-5.05%
CLLS Cellectis S.A.
1.7600
-4.86%
CLSD Clearside Biomedical, Inc.
1.0200
+2.00%
STOK Stoke Therapeutics, Inc.
12.06
-2.11%
OCUL Ocular Therapeutix, Inc.
8.69
-2.25%
OKUR OnKure Therapeutics, Inc.
9.86
-8.96%